May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...

Pfizer (PFE) stock is in focus as the company starts Phase 3 infant trials for the 25-valent pneumococcal vaccine after ...

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Pfizer Inc.

Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Danuglipron, a weight-loss pill, won’t continue its stages of testing after a person in a clinical trial was reportedly injured. Pfizer plans to explore other obesity treatments for testing. Pfizer is ...

VERITAC-2 trial shows vepdegestrant improves progression-free survival in ESR1-mutant breast cancer, marking a clinical milestone for PROTAC therapy. The trial did not reach statistical significance ...

Pfizer's 25vPnC pneumococcal vaccine shows up to 15-fold higher antibody levels in infants, advancing to late-stage trials ...